MedPath

The effects of berberis integerrima extract on the non-alcoholic fatty liver disease (NAFLD)

Not Applicable
Not yet recruiting
Conditions
on-alcoholic fatty liver disease (NAFLD).
Nonalcoholic steatohepatitis (NASH)
K75.81
Registration Number
IRCT20210427051098N6
Lead Sponsor
Yazd University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
60
Inclusion Criteria

Age 18 and older
Diagnosis of the disease by ultrasound with a standard method
ALT >30 IU/L in men and ALT >19 IU/L in women
BMI higher than 18.5 and less than 30

Exclusion Criteria

Taking corticosteroids
Pregnancy and breastfeeding
Alcohol consumption (men: ethanol > 140 g per week, women: ethanol > 70 g per week)
History of diseases including liver cirrhosis, viral hepatitis, cardiovascular diseases, cancer
Medication history including corticosteroids, non-steroidal anti-inflammatory drugs, drugs affecting blood sugar, lipid profile, body weight and liver function.
Disease relapse and patient hospitalization
Barberry allergy

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum levels of alanine transaminase enzyme. Timepoint: Before intervention- after intervention (12 weeks after receiving barberry extract or placebo). Method of measurement: Enzymatic method.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath